Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body



Status:Recruiting
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:7/29/2017
Start Date:August 2014
End Date:December 2018
Contact:UC Cancer Institute Clinical Trials Office
Phone:513-584-7698

Use our guide to learn which trials are right for you!

Phase I Study to Evaluate the Feasibility of Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body

The purpose of this study is to test the safety of focused radiation (Stereotactic Body
Radiation Therapy, SBRT) on patients with pancreatic cancer that will be removed surgically.


Inclusion Criteria:

- Age >18 years.

- Histologically confirmed pancreatic adenocarcinoma of the head and/or body; at least
the majority of the histopathologic specimen must be identified as adenocarcinoma.

- Pancreatic tumors must be considered resectable at time of treatment planning.
Definition of resectable: no metastases, less than 180 degree involvement of superior
mesenteric vein or portal vein, no involvement of hepatic artery, superior mesenteric
artery or celiac artery

- No active infection requiring hospitalization

- Adequate labs

- Life expectancy > 3 months.

- Patient is to have received chemotherapy prior to enrollment. This will typically
consist of 3-4 cycles of chemotherapy. Patients will have a 2 week break between last
chemotherapy administration and start of SBRT.

Exclusion Criteria:

- Presence of metastatic disease.

- Infections requiring systemic antibiotic treatment.
We found this trial at
1
site
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
Principal Investigator: Michelle Mierzwa, MD
Phone: 513-584-7698
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials